STAT+: Democrats take new step toward investigating Trump’s drug pricing deals

WASHINGTON — The incoming Democratic chairs of key committees have taken a new step toward investigating the most-favored nation drug pricing agreements between drugmakers and the Trump administration. The drug pricing deals are expected to be a top health care oversight priority for Democrats once they take the majority in January. Earlier this year, the top Democrats on the Senate Finance Committee and the House Energy and Commerce, Ways and Means, and Education and Labor committees requested that companies disclose the details of the deals they struck to tie Medicaid drug prices to levels in peer countries. Since then, additional companies have signed agreements with the Trump administration. A new round of letters were recently sent to all 27 companies, according to a congressional source familiar with the letters. Endpoints News first reported the new requests. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe